Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.

by Spencer, Andrew, Samoilova, Olga, Chng, Wee-Joo, Labotka, Richard, Li, Cong, Wu, Kwang-Wei, Saxena, Nakul, Yan, Xu, Lee, Jae Hoon, Beksac, Meral
Published 2023

Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)

by Liu, Jin, Hu, Xiaoxia, Jia, Yanchun, Lu, Jin, Lee, Jae Hoon, Kim, Kihyun, Chen, Wenming, Liu, Aijun, Liu, Yang, Chen, Q, Zhang, Chunyang, Suh, Cheolwon, Kim, Min Kyoung, Zhou, Fan, Chng, Wee Joo, Kumar, Shaji K, Durie, Brian, Hou, Jian, Fu, Weijun, Du, Juan
Published 2022

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network

by Soekojo, Cinnie Yentia, Kim, Kihyun, Huang, Shang-Yi, Chim, Chor-Sang, Takezako, Naoki, Asaoku, Hideki, Kimura, Hideo, Kosugi, Hiroshi, Sakamoto, Junichi, Gopalakrishnan, Sathish Kumar, Nagarajan, Chandramouli, Wei, Yuan, Moorakonda, Rajesh, Lee, Shu Ling, Lee, Je Jung, Yoon, Sung-Soo, Kim, Jin Seok, Min, Chang Ki, Lee, Jae-Hoon, Durie, Brian, Chng, Wee Joo
Published 2022